SUNPHARMA.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Stats
Dagens volum	1.09M
Gjennomsnittsvolum	2.81M
Markedsverdi	3 650.74B
EPS	INR10.50 ( 2024-01-31 )
Neste inntjeningsdato	( INR6.83 ) 2024-05-24
Last Dividend	INR4.00 ( 2023-07-28 )
Next Dividend	INR0 ( N/A )
P/E	41.06
ATR14	INR1.209 (0.08%)

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: 0.00 (neutral)

Signal:(54.865) Neutral

Sun Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sun Pharmaceutical Korrelasjon - Valuta/Råvare

0.55
( weak )

0.63
( weak )

0.31
( neutral )

0.53
( weak )

0.77
( moderate )

-0.02
( neutral )

Sun Pharmaceutical Økonomi

Annual	2022
Omsetning:	INR432.79B
Bruttogevinst:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Omsetning:	INR432.79B
Bruttogevinst:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Omsetning:	INR384.26B
Bruttogevinst:	INR267.19B (69.53 %)
EPS:	INR13.60

FY	2021
Omsetning:	INR334.98B
Bruttogevinst:	INR236.13B (70.49 %)
EPS:	INR12.10

Financial Reports:

No articles found.

Sun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.00 (N/A)	INR0 (N/A)	INR7.50 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Sun Pharmaceutical Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.54 - low (17.82%) | Divividend Growth Potential Score: 4.46 - Stable (10.76%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0208	1996-06-24
Last Dividend	INR4.00	2023-07-28
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR59.60	--
Avg. Dividend % Per Year	0.77%	--
Score	2.84	--
Div. Sustainability Score	3.54
Div.Growth Potential Score	4.46
Div. Directional Score	4.00	--

Next Divdend (Est)
(2024-06-03)

INR4.08 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.39%
2019	INR2.75	0.63%
2020	INR4.00	0.92%
2021	INR7.50	1.26%
2022	INR10.00	1.18%
2023	INR11.50	1.15%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%
ELDEHSG.NS	Dividend Junior	2023-09-15	Annually	3	0.63%
AHLADA.NS	Dividend Junior	2023-09-22	Annually	6	0.95%
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.191	1.500	6.18	9.28	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	43.19	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
freeCashFlowPerShareTTM	21.49	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.774	1.000	0.428	0.428	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.23	7.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	41.14	1.000	5.95	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	21.49	2.00	2.84	10.00	[0 - 30]
dividendYielPercentageTTM	0.819	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.259	1.500	-1.608	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.110	1.000	9.74	0	[0.1 - 0.5]
Total Score				4.46

Sun Pharmaceutical

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.